CVS Caremark settles FTC litigation, ends investigations into PBM practices

CVS Health reached a global settlement with the FTC, resolving litigation and investigations into its PBM practices. Key commitments include ending spread pricing, enhancing transparency, delinking manufacturer compensation from list prices, capping insulin costs at $25/month, and adjusting independent pharmacy reimbursements.

CVS Health reached a global settlement with the FTC, resolving all outstanding litigation and investigations tied to its PBM and affiliated pharmacy operations. * The FTC matters covered rebate practices, pharmacy network contracting, vertical integration, pricing transparency, and affordability. * Settlement commitments include shifting standard commercial offerings away from spread pricing, expanding pricing and rebate reporting, delinking manufacturer compensation from list prices. * CVS Caremark also agreed to align member cost sharing more closely with net drug costs, add an insulin cap of USD 25 per month, adjust reimbursement for independent pharmacies. * Implementation starts under FTC timelines, removing the need for continued litigation and investigations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVS Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607141505PR_NEWS_USPR_____NE03484) on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

CVS Health reached a global settlement with the FTC, resolving all outstanding litigation and investigations tied to its PBM and affiliated pharmacy operations. * The FTC matters covered rebate practices, pharmacy network contracting, vertical integration, pricing transparency, and affordability. * Settlement commitments include shifting standard commercial offerings away from spread pricing, expanding pricing and rebate reporting, delinking manufacturer compensation from list prices. * CVS Caremark also agreed to align member cost sharing more closely with net drug costs, add an insulin cap of USD 25 per month, adjust reimbursement for independent pharmacies. * Implementation starts under FTC timelines, removing the need for continued litigation and investigations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVS Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607141505PR_NEWS_USPR_____NE03484) on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)